ABHD6 as a novel drug target for obesity, non-alcoholic fatty liver disease (NASH) and cardiovascular disease (CVD)

Obesity, type 2 diabetes (T2D) and heart diseases have skyrocketed. Controlling glucose usage and insulin balance can substantially decrease the morbidity and improve the quality of life in affected individuals. Dysfunctional insulin action and energy balance in the body is associated with excessive non-adipose fat storage, particularly in the liver, and elevated circulating lipids, which contribute to heart disease. Obesity, a primary cause of T2D, is linked with white fat build-up and gradual loss of proper action of insulin. Unlike fat-storing white fat, brown fat is thermogenic, and its calorie-burning properties can reduce fat burden in the body. Increasing the brown fat function and promoting conversion of white fat to brown-like fat help lower the calorie burden and enhance insulin function and restore normal glucose usage. TO BE CONT’D

Faculty Supervisor:

Marc Prentki

Student:

Pegah Poursharifi

Partner:

Institut de Recherches Servier

Discipline:

Food science

Sector:

Pharmaceuticals

University:

Program: